TOPK-p38/JNK-IN-1 (Compound B12) is an orally active inhibitor of the TOPK-p38/JNK signaling pathway, exhibiting an IC50 of 2.14 μM for NO production inhibition. It demonstrates anti-inflammatory properties by inhibiting downstream protein phosphorylation and preventing TOPK degradation [1].

TOPK-p38/JNK-IN-1 (Compound B12) (10 μM, 1 h) inhibits NO production in RAW264.7 cells and suppresses LPS-induced TOPK/NF-jB/p38/JNK activation (0-10 μM, 1 h for RAW264.7; 6 h for HaCaT) [1]. It also inhibits cell proliferation in a dose-dependent manner (0-100 μM, 24 h for RAW264.7; 0-50 μM, 6 h for HaCaT) [1]. In Cell Viability Assays on RAW264.7 cells, concentrations of 4 μM, 20 μM, and 100 μM for 24 h inhibited cell proliferation dose-dependently [1]. In Cell Proliferation Assays on HaCaT cells, pre-treatment with various concentrations (0.78-50 μM) for 6 h followed by 24 h incubation with LPS (100 μg/mL) inhibited LPS-induced excessive proliferation dose-dependently [1]. Western Blot Analysis on RAW264.7 and HaCaT cells (2.5-10 μM) pre-treated for 1 h or 6 h showed dose-dependent inhibition of iNOS and COX-2 expression, affected TOPK phosphorylation, and inhibited P38/JNK protein phosphorylation and NF-κB p65 nuclear translocation [1].

TOPK-p38/JNK-IN-1 (Compound B12), administered orally at 20-40 mg/kg daily for a week to 6-8-week-old female BALB/c mice, effectively mitigated psoriasis-like skin inflammation induced by 62.5 mg of IMQ cream. Treatment significantly reduced scales, thickness, and erythema, and histopathological analysis showed alleviated hyperkeratosis, acanthocyte proliferation, and inflammatory cell infiltration. Compound B12 also dose-dependently inhibited the expression of psoriasis-related proteins (p-STAT3, p-TOPK, TOPK, p-p38, p-JNKs, PCNA, p-H2AX) in the skin tissues of the mice.